Roivant Shares Rise 8.1% After Positive Phase 3 Uveitis Results
Roivant shares gained 8.1% to $37.74 in premarket trading after positive phase 3 trial results for a treatment for non-infectious uveitis.
By Kelly CloonanShares of Roivant rose on positive results from phase 3 trials evaluating a treatment for non-infectious uveitis (NIU), a condition that's a leading cause of blindness.The stock gained 8.1% to $37.74 in premarket trading on Wednesday. At Tuesday's market close, shares were already u…